GlassScriptPhysician profile
Maranatha S Gabaud
NPI 1275988701
$4,843.61
in general payments reported to CMS, 2019-2025
29 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,280 · 2023: $802 · 2024: $1,080 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.18 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,256.76 | 2022-2024 | Aveir |
| Novartis Pharmaceuticals Corporation | $345.04 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.69 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $217.16 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $191.70 | 2022-2025 | Farxiga |
| Boston Scientific Corporation | $181.53 | 2024-2025 | Cds - Mct/Cem Monitoring |
| Actelion Pharmaceuticals US, INC. | $156.40 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $148.97 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $132.54 | 2022-2024 | Verquvo |
| Novo Nordisk INC | $131.73 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $99.89 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $92.38 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $78.07 | 2023-2024 | Repatha |
| Baxter Healthcare | $73.68 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Medicomp INC | $70.55 | 2024 | Telepatch Cardiac Monitor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $60.71 | 2022-2025 | Mcot |
| Lexicon Pharmaceuticals, INC. | $58.48 | 2023 | Inpefa |
| Inspire Medical Systems, INC. | $41.84 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.56 | 2022-2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $39.83 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $29.09 | 2025 | Amvuttra |
| Daiichi Sankyo INC. | $27.39 | 2025 | Injectafer |
| Celgene Corporation | $22.72 | 2025 | Camzyos |
| Vital Connect, INC | $20.95 | 2023 | Vitalpatch Rtm |
| Convatec INC. | $19.19 | 2025 | |
| Esperion Therapeutics, INC. | $17.93 | 2025 | Nexletol |
| Cvrx, INC. | $17.93 | 2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2024 | |
| Scpharmaceuticals INC. | $14.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maranatha Gabaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.